{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-24-000120","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.707991+00:00","generated_at":"2026-06-02T19:11:19.932542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Denali Q1 net loss $101.8M, cash $1.43B; reports pipeline progress and $500M PIPE","bullets":["Net loss $101.8M vs $109.8M YoY; zero collaboration revenue vs $35.1M in Q1 2023.","R&D expense $107.0M, down from $128.8M; G&A $25.2M, down from $27.1M.","Completed $500M PIPE financing in February; raised cash to $1.43B.","Tividenofusp alfa (MPS II) shows sustained biomarker normalization; FDA may consider accelerated path.","Phase 1/2 for DNL126 (MPS IIIA) dosed; Phase 2/3 COMPASS enrollment expected to complete in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-24-000120","json":"https://secwatch.observer/filing/0001714899-24-000120.json","markdown":"https://secwatch.observer/filing/0001714899-24-000120.md","text":"https://secwatch.observer/filing/0001714899-24-000120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000120/0001714899-24-000120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000120/dnli-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:11:19.932542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f18397fca688c5d00000efe21bbe6bb97cd281cb","claim":"Denali Therapeutics Inc. reported the first quarter ended March 31, 2024 results: revenue There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended, net income Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter.","evidence_excerpt":"Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter ended March 31, 2023. There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000120/0001714899-24-000120-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended"},{"label":"Net income","value":"Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}